

## REVIEW ARTICLE OPEN ACCESS

# Towards the Development of a Conceptual Framework of the Determinants of Pre-eclampsia: A Hierarchical Systematic Review of Biomarkers

Terteel Elawad<sup>1</sup> | Hiten D. Mistry<sup>1,2</sup> | Mai-Lei Woo Kinshella<sup>3</sup>  | Marianne Vidler<sup>3</sup> | Marie-Laure Volvert<sup>1</sup> | Helen Elwell<sup>4</sup> | Veronique Filippi<sup>5</sup> | Kelly Pickerill<sup>3</sup> | Rachel Craik<sup>1</sup>  | Joel Singer<sup>6</sup> | Rosemary Townsend<sup>7</sup> | Hannah Blencowe<sup>5</sup> | Eleni Z. Tsigas<sup>8</sup> | Jeffrey N. Bone<sup>3</sup>  | Peter von Dadelszen<sup>1,3</sup>  | Laura A. Magee<sup>1,3</sup>  | the PRECISE Network

<sup>1</sup>Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK | <sup>2</sup>Department of Population Health Sciences, College of Life Sciences, University of Leicester, Leicester, UK | <sup>3</sup>Department of Obstetrics and Gynaecology, BC Children's and Women's Hospital and University of British Columbia, Vancouver, British Columbia, Canada | <sup>4</sup>BMA Library, British Medical Association, London, UK | <sup>5</sup>Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK | <sup>6</sup>School of Population and Public Health, Centre for Health Evaluation and Outcome Sciences, University of British Columbia, Vancouver, British Columbia, Canada | <sup>7</sup>Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK | <sup>8</sup>Preeclampsia Foundation, Melbourne, Florida, USA

**Correspondence:** Laura A. Magee ([laura.a.magee@kcl.ac.uk](mailto:laura.a.magee@kcl.ac.uk))

**Received:** 2 August 2024 | **Revised:** 18 February 2025 | **Accepted:** 8 April 2025

**Funding:** The work was supported by funding from a United Kingdom Research and Innovation GCRF GROW award (MR/P027938/1) and an NIHR–Wellcome Partnership for Global Health Research Collaborative Award (reference 217 123/Z/19/Z). M.-L.W.K. was supported by the Vanier Canada Graduate Scholarship, funded by the Government of Canada through the Canadian Institutes of Health Research (CIHR).

**Keywords:** Biomarkers | Conceptual framework | Pre-eclampsia

## ABSTRACT

**Background:** Pre-eclampsia is a leading cause of maternal and perinatal morbidity and mortality. There are several determinants of individual pregnant women's risk of developing pre-eclampsia, including biomarkers and ultrasound markers.

**Objective:** A conceptual framework to collate and summarise the extensive body of literature on biomarkers (including ultrasound markers) associated with pre-eclampsia, through a hierarchical systematic literature review.

**Search Strategy:** Medline, Embase, Health Technology Assessments, Database of Abstracts of Reviews of Effects, Cochrane Library were searched until April 2024.

**Selection Criteria:** Reviews and cohort studies (> 100 participants) reporting biomarkers associated with pre-eclampsia were included.

**Data Collection and Analysis:** Studies were screened by title, then abstract and full text. Evidence was prioritised from umbrella reviews, followed by systematic reviews and then observational studies. Associations were assessed for strength of association and quality of evidence using GRADE.

**Main Results:** The biomarker domain included 40 individual determinants of pre-eclampsia. Of these, there were 18 biomarkers with definite or probable associations based on moderate-strong quality evidence across markers of angiogenic imbalance,

Terteel Elawad and Hiten D. Mistry shared first authorship.

Peter von Dadelszen and Laura A. Magee shared senior authorship.

See Table S1 for all members of the PRECISE Network.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2025 The Author(s). BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.

fetal-placental unit function, inflammatory and immune markers, and physiological markers. Vascular endothelial growth factor, human chorionic gonadotropin, inhibin-A, maternal serum placental protein-13, and interferon-gamma had definite associations based on high-quality evidence.

**Conclusion:** Biomarkers associated with the development of pre-eclampsia highlight the multi-factorial aetiology of the syndrome. The addition of biomarkers, including ultrasound, will optimise the prediction of pre-eclampsia and enable individualised risk stratification.

## 1 | Introduction

Pre-eclampsia is a severe pregnancy complication, distinguished by the emergence of *de novo* hypertension after 20 weeks of gestation, accompanied by proteinuria and/or evidence of maternal acute kidney injury, liver dysfunction, neurological features, haemolysis or thrombocytopaenia or fetal growth restriction [1]. Globally, it ranks as the second most prevalent cause of maternal mortality, resulting in more than 46 000 maternal and 500 000 perinatal deaths annually [2]. This burden is particularly pronounced in low- and middle-income countries. Furthermore, pre-eclampsia is associated with lifelong consequences for both the mother and her child, including increased risks of cardiovascular, renal and metabolic disease [2, 3].

As the pathophysiology of pre-eclampsia remains to be fully elucidated, there is a need to further understand the determinants to develop and improve risk screening and preventative strategies [4]. Building on extensive research and the development of several biomarkers for pre-eclampsia that reflect the heterogeneous nature of the syndrome [4, 5], cost-effective, safe, and reliable methods to predict pre-eclampsia have been developed and, for preterm disease, have guided effective evidence-based interventions [6–9].

The aim of this study was to develop a conceptual framework that systematically summarises the current high-quality evidence in relation to biomarkers, including ultrasound markers, of pre-eclampsia risk. A conceptual framework maps the literature on biomarkers predictive of the development of pre-eclampsia by the strength of association and quality of the evidence and has the potential to inform prevention strategies and risk stratification to guide surveillance and care pathways.

## 2 | Material and Methods

Detailed methodology for this study has been previously described [10], but is described briefly below. The biomarkers conceptual framework is part of the larger PRECISE conceptual framework on determinants of pre-eclampsia.

### 2.1 | Search Strategy

We employed the methods of Hiatt et al. [11], to develop a criteria-based model of determinants using a systematic process with the aim of building a conceptual framework to describe a comprehensive multi-factorial model of biomarkers (including ultrasound markers), determinants of pre-eclampsia. A

broad working model of known determinants was assembled by the 'PREgnancy Care Integrating translational Science, Everywhere' (PRECISE) Network [12] (Table S1) based on variables found to have significant associations with pre-eclampsia from pooled results from umbrella reviews of systematic reviews [13, 14]. The search strategy was developed in consultation with a clinical librarian at the British Medical Association (HE), and designed to identify the highest level of evidence. Detailed nutritional biomarkers have previously been published by our group [15] and thus not included in this search. Systematic searches were conducted on Medline, Embase, Evidence-Based Medicine Reviews (Health Technology Assessments, Database of Abstracts of Reviews of Effects, Cochrane Library databases), Google Scholar, and reference lists from the database inception to April 2024 for relationships between biomarkers and pre-eclampsia. Medical subject heading and free text words were used to extract relevant studies from the database; search terms are reported in Table S2.

Following the methods of Hiatt et al. [11], studies were selected according to a hierarchy of evidence that prioritised umbrella reviews (systematic reviews of reviews), followed by systematic reviews with meta-analyses and finally, large (at least 100 participants), observational cohort studies. Cohort studies with fewer than 100 participants, cross-sectional surveys, case-controlled studies, case reports/series, qualitative reviews, and editorials were excluded.

### 2.2 | Data Extraction

Titles and abstracts of articles were screened by the review team (TE, MWK, HDM) to assess eligibility, with all potentially eligible studies undergoing full-text review. Studies were included if they reported on biomarkers associated with the incidence of pre-eclampsia. Studies that reported only on other forms of hypertensive disorders of pregnancy or pregnancy hypertension in general were excluded. Data were abstracted from umbrella reviews and their source reviews where applicable, individual reviews and cohort studies. Abstracted data included general study characteristics and strength of association between each biomarker and pre-eclampsia and were expressed as odds ratios (OR), relative risk (RR), as reported in the reviews or individual studies. In addition, diagnostic OR (DOR), likelihood ratios (LR) and area under the receiver operating characteristic (AUROC) curve were used when included.

### 2.3 | Quality of the Evidence

The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) [16, 17] approach was used to assess

**TABLE 1** | Strength of association between risk factors and pre-eclampsia based on point estimates of various summary measures.

|          | RR or OR <sup>a</sup> |                | DOR <sup>b</sup> | LR <sup>c</sup> |           | AUC point estimate <sup>d</sup> |
|----------|-----------------------|----------------|------------------|-----------------|-----------|---------------------------------|
|          | Decreases risk        | Increases risk |                  | LR+             | LR–       |                                 |
| Definite | <0.33                 | ≥ 3.00         | ≥ 100            | > 10            | <0.1      | > 0.8                           |
| Probable | 0.33–0.67             | 1.50–2.99      | > 25 to < 100    | 5.01–10.0       | 0.10–0.19 | 0.70–0.80                       |
| Possible | > 0.67 to < 0.9       | 1.10–1.49      | > 4 to ≤ 25      | 2.01–5.0        | 0.20–0.50 | 0.51–0.69                       |
| Unlikely | 0.90–1.09             |                | 1–4              | 1.0–2.0         | 0.51–0.99 | ≤ 0.50                          |

Abbreviations: LR, likelihood ratio; LR–, negative LR; LR+, positive LR; OR, odds ratio; RR, relative risk.

<sup>a</sup>Based on Hiatt and modification of Harvard Cancer Risk Index.

<sup>b</sup>Based on LR+ and LR– criteria and definition of DOR as LR+/LR–.

<sup>c</sup>Based on UpToDate.

<sup>d</sup>Based on Mandrekar J Thorac Oncol 2010. In general, an AUC of 0.5 suggests no discrimination (i.e., ability to diagnose patients with and without the disease or condition based on the test), 0.7 to 0.8 is considered acceptable, 0.8 to 0.9 is considered excellent, and more than 0.9 is considered outstanding.

the quality of evidence, using four levels: high, moderate, low, and very low. Umbrella or systematic reviews are classed as high quality, compared to single observational studies which were considered low certainty of evidence that could be upgraded for large effect sizes or evidence of a dose–response relationship [17]. The certainty of the evidence was also lowered due to various factors including potential bias, inconsistency (significant variability  $I^2 > 50\%$ ), imprecise measurements (wide confidence intervals), and potential publication bias (asymmetric funnel plot).

The criteria for strength of association between each biomarker and pre-eclampsia were based on point estimates of summary measures adapted from Hiatt et al. [11] (see Table 1). The strength of the relationship was categorised as definite (≥ 3.00 or < 0.33), probable (1.50–2.99 or 0.33–0.67), possible (1.10–1.49 or 0.68–0.89), and unlikely (0.90–1.09). We employed both RR and OR interchangeably for the model, as ORs provide a reasonable estimate of the RR when the outcome is observed in < 10% of both exposed and unexposed populations [18].

The strength of association between variables based on DOR was categorised as follows following expert guidance from LAM/JS and based on Mahutte & Dulebi, 2024 [19]: definite: ≥ 100, probable: > 25 to < 100, possible: > 4 to ≤ 25, or not significant: 1–4. The strength of association between variables based on likelihood ratios (LR) was categorised according to UpToDate [19]. The following four categories were used: definite: > 10 or < 0.1, for a positive or negative likelihood ratio, respectively; probable: 5.01–10.0 or 0.10–0.19, for a positive or negative likelihood ratio, respectively; possible: 2.01–5.0 or 0.20–0.50, for a positive or negative likelihood ratio, respectively; or not significant: 1.0–2.0 or 0.51–0.99, for a positive or negative likelihood ratio, respectively.

The strength of association between variables based on AUROC curve, as reported in reviews or individual studies, was categorised according to diagnostic test assessment. In general, an AUROC of 0.5 suggests no discrimination (i.e., ability to diagnose patients with and without the disease or condition based on the test), 0.7 to 0.8 is considered acceptable, 0.8 to 0.9 is considered excellent, and more than 0.9 is considered outstanding [20]. The following four categories were

used: definite: > 0.8, probable: 0.70–0.80, possible: 0.51–0.69, or unlikely: ≤ 0.50.

### 3 | Results

Forty biomarkers were identified. Table 2 presents the framework of biomarkers according to their strength of association and quality of the evidence, with details on timing of measurement and onset of pre-eclampsia where available (Data S1). Thirty-eight biomarkers were based on evidence from umbrella reviews or systematic reviews [14, 21–23, 25–34, 36–42]. Only two biomarkers were primarily based on evidence from a cohort study [35]. GRADE assessments for each biomarker are reported in Data S2.

Nine biomarkers were identified as having a definite association with pre-eclampsia, including vascular endothelial growth factor (VEGF) [14, 21], beta human chorionic gonadotropin (β-hCG) [14, 25], inhibin-A [14, 22], placental protein 13 (PP13) [14, 22], and interferon-gamma (IFN-γ) [14, 30], based on high-quality evidence. Arterial stiffness [14, 36] and serum concentration of nitric oxide (NO) [14, 37] were based on moderate-quality evidence due to heterogeneity, risk of bias, and imprecision, and upgraded for very large effect sizes. Higher peak ratio [39] and second peak systolic velocity [39] on ophthalmic artery Doppler were based on low-quality evidence due to heterogeneity and potential imprecision (< 1000 total participants included in the meta-analysis).

Eleven biomarkers had a probable association with pre-eclampsia. Probable associations based on high-quality evidence included soluble endoglin (sENG) [14, 21], soluble fms-like tyrosine kinase-1 (sFlt-1) [14, 21], pregnancy-associated plasma protein A (PAPP-A) [14, 22], systolic blood pressure (sBP) 120–129 and diastolic blood pressure (dBP) above 80 mmHg before 20 weeks gestation [35], sBP 130–139 mmHg or dBP 80–89 mmHg before 20 weeks gestation [35], early pregnancy glycated haemoglobin (HbA1c) [41], ischaemia-modified albumin [28], uric acid [28], and malondialdehyde [28]. Placental growth factor (PlGF) [14, 21] and anticardiolipin antibodies [14, 32] were probable associations based on moderate-quality evidence. Evidence was downgraded for heterogeneity and potential publication bias, and upgraded for large effect sizes for

**TABLE 2** | Summary of biomarkers for pre-eclampsia, overall and by timing of measurement and pre-eclampsia onset.

| Biomarker                                         | Effect estimate<br>(95% CI)                        | N<br>studies | N<br>participants | I <sup>2</sup> | Direction of effect                              | Strength of<br>association | Certainty of<br>evidence |
|---------------------------------------------------|----------------------------------------------------|--------------|-------------------|----------------|--------------------------------------------------|----------------------------|--------------------------|
| Angiogenic imbalance                              |                                                    |              |                   |                |                                                  |                            |                          |
| PlGF [14, 21]                                     | OR 0.36 (0.25, 0.54)                               | 26           | 4425              | 84%            | Higher levels as a<br>protective factor          | Probable                   | Moderate                 |
| Early onset PE <sup>a</sup> [22]                  | OR 3.4<br>(1.6, 7.2)                               | 4            | 1729              | 87%            | Abnormal <sup>b</sup> levels<br>as a risk factor | Definite                   | Moderate                 |
| Late-onset PE <sup>a</sup> [22]                   | OR 1.85<br>(0.7, 4.33)                             | 3            | 1262              | 89%            | N/A                                              | Unlikely                   | Low                      |
| sENG [14, 21]                                     | OR 2.66<br>(1.53, 4.63)                            | 19           | 3141              | 91%            | Higher levels as<br>a risk factor                | Probable                   | High                     |
| Early onset PE <sup>a</sup> [22]                  | OR 18.5<br>(8.4, 41.0)                             | 2            | 2143              | 14%            | Abnormal <sup>c</sup> levels<br>as a risk factor | Definite                   | High                     |
| Late-onset PE <sup>a</sup> [22]                   | OR 2.1<br>(1.9, 2.4)                               | 3            | 2326              | 0%             | Abnormal <sup>c</sup> levels<br>as a risk factor | Probable                   | High                     |
| sFlt-1 [14, 21]                                   | OR 2.38<br>(1.47, 3.86)                            | 32           | 5230              | 93%            | Higher levels as<br>a risk factor                | Probable                   | High                     |
| Early onset PE <sup>a</sup> [22]                  | OR 1.2<br>(0.33, 4.41)                             | 3            | 569               | 79%            | N/A                                              | Unlikely                   | Low                      |
| Late-onset PE <sup>a</sup> [22]                   | OR 1.03<br>(0.62, 1.74)                            | 3            | 778               | 50%            | N/A                                              | Unlikely                   | Low                      |
| VEGF [14, 21]                                     | OR 0.10<br>(0.01, 1.53)                            | 4            | 265               | 96%            | Higher levels as a<br>protective factor          | Definite                   | High                     |
| Markers of fetal placental unit function          |                                                    |              |                   |                |                                                  |                            |                          |
| AFP ≥ 2.00 MoM<br>(2nd trimester) [13, 23]        | LR+ 2.36<br>(1.46–3.83)<br>LR– 0.96<br>(0.95–0.98) | 10           | 103 627           | N/A            | Higher levels as<br>a risk factor                | Possible                   | Low                      |
| AFP ≥ 2.00 MoM on preterm PE <sup>d</sup><br>[24] | RR 2.6<br>(0.6, 11.1)                              | 1            | 7929              | N/A            | N/A                                              | Unlikely                   | Very low                 |
| AFP ≥ 2.00 MoM on term PE <sup>d</sup><br>[24]    | RR 1.1<br>(0.3, 4.5)                               | 1            | 7929              | N/A            | N/A                                              | Unlikely                   | Very low                 |

(Continues)

TABLE 2 | (Continued)

| Biomarker                                         | Effect estimate<br>(95% CI) | N<br>studies | N<br>participants | I <sup>2</sup> | Direction of effect               | Strength of<br>association | Certainty of<br>evidence |
|---------------------------------------------------|-----------------------------|--------------|-------------------|----------------|-----------------------------------|----------------------------|--------------------------|
| β-hCG [14, 25]                                    | OR 88.7<br>(4.31, 1824)     | 12           | 8935              | 100%           | Higher levels as<br>a risk factor | Definite                   | High                     |
| 1st-trimester measurement [26]                    | SMD 0.002<br>(−0.12, 0.13)  | 15           | 24 591            | 76%            | N/A                               | N/A                        | Low                      |
| 2nd-trimester measurement [26]                    | SMD 0.37<br>(0.19, 0.54)    | 6            | 3547              | 60%            | Higher levels in PE group         | N/A                        | Moderate                 |
| hCG > 2.0 MoM on preterm PE <sup>d</sup><br>[24]  | RR 3.8<br>(1.5, 9.8)        | 1            | 7929              | N/A            | Higher levels as<br>a risk factor | Definite                   | Moderate                 |
| hCG > 2.0 MoM<br>on term PE <sup>d</sup> [24]     | RR 2.0<br>(0.9, 4.2)        | 1            | 7929              | N/A            | N/A                               | Unlikely                   | Very low                 |
| Inhibin-A (1st trimester) [14, 22]                | OR 3.57<br>(1.68, 7.61)     | 3            | 1215              | 21%            | Higher levels as<br>a risk factor | Definite                   | High                     |
| Early onset PE <sup>a</sup> [22]                  | OR 4.1<br>(1.9, 8.8)        | 1            | 234               | N/A            | Higher levels as<br>a risk factor | Definite                   | Moderate                 |
| Late-onset PE <sup>a</sup> [22]                   | OR 1.9<br>(1.4, 2.8)        | 2            | 441               | 0%             | Higher levels as<br>a risk factor | Probable                   | Low                      |
| PAPP-A (1st trimester) [14, 22]                   | OR 2.05<br>(1.62, 2.59)     | 9            | 53 355            | 45%            | Low levels as a risk factor       | Probable                   | High                     |
| Early onset PE <sup>a</sup> [22]                  | OR 4.8<br>(2.5, 22.5)       | 4            | 9713              | 72%            | Low levels as a risk factor       | Definite                   | Moderate                 |
| Late-onset PE <sup>a</sup> [22]                   | OR 1.44<br>(0.89, 2.32)     | 2            | 8726              | 0%             | N/A                               | Unlikely                   | Low                      |
| PP13 (1st trimester) [14, 22]                     | OR 4.43<br>(2.86, 6.85)     | 4            | 4061              | 49%            | Low levels as a risk factor       | Definite                   | High                     |
| Early onset PE <sup>a</sup> [22]                  | OR 7.5<br>(2.5, 22.5)       | 3            | 3184              | 69%            | Low levels as a risk factor       | Definite                   | High                     |
| Markers of lipid metabolism and oxidative stress  |                             |              |                   |                |                                   |                            |                          |
| HDL-c<br>(1st & 2nd trimester, mg/dL) [13,<br>27] | WMD −0.48<br>(−3.31, 2.34)  | 10           | 7369 <sup>e</sup> | 73%            | N/A                               | N/A                        | Low                      |

(Continues)

TABLE 2 | (Continued)

| Biomarker                                                  | Effect estimate<br>(95% CI)  | N<br>studies | N<br>participants | I <sup>2</sup> | Direction of effect       | Strength of<br>association | Certainty of<br>evidence |
|------------------------------------------------------------|------------------------------|--------------|-------------------|----------------|---------------------------|----------------------------|--------------------------|
| HDL-c<br>(3rd trimester, mg/dL) [13, 27]                   | WMD -8.86<br>(-11.50, -6.21) | 41           | 7369 <sup>e</sup> | 95%            | Lower levels in PE group  | N/A                        | Low                      |
| LDL-c<br>(1st & 2nd trimester, mg/dL) [13, 27]             | WMD 3.89<br>(-0.19, 7.97)    | 9            | 7369 <sup>e</sup> | 13%            | N/A                       | N/A                        | Moderate                 |
| LDL-c<br>(3rd trimester, mg/dL) [13, 27]                   | WMD 10.92<br>(-0.59, 22.42)  | 36           | 7369 <sup>e</sup> | 97%            | N/A                       | N/A                        | Low                      |
| Total cholesterol<br>(1st & 2nd trimester, mg/dL) [13, 27] | WMD 12.49<br>(3.44, 21.54)   | 11           | 7369 <sup>e</sup> | 56%            | Higher levels in PE group | N/A                        | Low                      |
| Total cholesterol<br>(3rd trimester, mg/dL) [13, 27]       | WMD 20.20 (8.70, 31.70)      | 46           | 7369 <sup>e</sup> | 99%            | Higher levels in PE group | N/A                        | Low                      |
| Triglycerides<br>(1st & 2nd trimester, mg/dL) [13, 27]     | WMD 25.08 (14.39, 35.77)     | 13           | 7369 <sup>e</sup> | 90%            | Higher levels in PE group | N/A                        | Low                      |
| Triglycerides<br>(3rd trimester, mg/dL) [13, 27]           | WMD 80.29<br>(51.45, 109.13) | 44           | 7369 <sup>e</sup> | 94%            | Higher levels in PE group | N/A                        | Low                      |
| Ischaemia-modified albumin<br>[28]                         | OR 3.38<br>(2.23, 4.53)      | 3            | 206               | 0%             | Higher levels in PE group | Probable                   | High                     |
| Uric acid [28]                                             | OR 3.05<br>(2.39, 3.71)      | 3            | 267               | 0%             | Higher levels in PE group | Probable                   | High                     |
| Malondialdehyde [28]                                       | OR 2.37<br>(1.03, 3.70)      | 3            | 224               | 16%            | Higher levels in PE group | Probable                   | High                     |
| Inflammatory and immune markers                            |                              |              |                   |                |                           |                            |                          |
| CRP [29]                                                   | SMD 0.52<br>(0.34, 0.69)     | 6            | 885               | 24%            | Higher levels in PE group | N/A                        | Moderate                 |
| IL-4 [29]                                                  | SMD 0.25 (0.076, 0.433)      | 2            | 437               | 0%             | Higher levels in PE group | N/A                        | Moderate                 |
| IL-6 [29]                                                  | SMD 0.60<br>(0.36, 0.83)     | 10           | 1236              | 70%            | Higher levels in PE group | N/A                        | Moderate                 |
| IL-8 [29]                                                  | SMD 0.53<br>(0.28, 0.77)     | 4            | 431               | 45%            | Higher levels in PE group | N/A                        | Moderate                 |

(Continues)

TABLE 2 | (Continued)

| Biomarker                                                          | Effect estimate<br>(95% CI) | N<br>studies | N<br>participants | I <sup>2</sup> | Direction of effect               | Strength of<br>association | Certainty of<br>evidence |
|--------------------------------------------------------------------|-----------------------------|--------------|-------------------|----------------|-----------------------------------|----------------------------|--------------------------|
| TNF- $\alpha$ [29]                                                 | SMD 0.59<br>(0.34, 0.83)    | 9            | 1331              | 74%            | Higher levels in PE group         | N/A                        | Low                      |
| IL-18 [14, 30]                                                     | OR 1.13<br>(0.49, 2.60)     | 10           | 772               | 89%            | N/A                               | Unlikely                   | Low                      |
| IFN- $\gamma$ [14, 30]                                             | OR 5.42<br>(1.14, 25.7)     | 12           | 1268              | 97%            | Higher levels as<br>a risk factor | Definite                   | High                     |
| HLA antibodies [14, 31]                                            | OR 0.93<br>(0.09, 9.77)     | 3            | 337               | 66%            | N/A                               | Unlikely                   | Very low                 |
| Anticardiolipin antibodies<br>$\geq 20$ units [14, 32]             | OR 2.85<br>(1.37, 5.95)     | 12           | 6747              | 69%            | Higher levels as<br>a risk factor | Probable                   | Moderate                 |
| sHCA-G<br>(1st trimester) [33]                                     | SMD -0.84<br>(-1.29, -0.38) | 3            | 643               | 54%            | Lower levels in PE group          | N/A                        | Low                      |
| sHCA-G<br>(2nd trimester) [33]                                     | SMD -0.48<br>(-1.16, 0.20)  | 3            | 346               | 75%            | N/A                               | N/A                        | Very low                 |
| sHCA-G<br>(3rd trimester) [33]                                     | SMD -0.39<br>(-0.71, -0.06) | 7            | 950               | 79%            | Lower levels in PE group          | N/A                        | Very low                 |
| ABO blood group                                                    |                             |              |                   |                |                                   |                            |                          |
| O blood group [34]                                                 | OR 0.95<br>(0.93, 0.97)     | 12           | 714 153           | 18%            | N/A                               | Unlikely                   | High                     |
| AB blood group [34]                                                | OR 1.46<br>(1.12, 1.91)     | 8            | 709 623           | 62%            | Higher in PE group                | Possible                   | Moderate                 |
| A blood group [34]                                                 | OR 1.02<br>(0.90, 1.16)     | 8            | 409 623           | 49%            | N/A                               | Unlikely                   | Moderate                 |
| B blood group [34]                                                 | OR 1.02<br>(0.98, 1.05)     | 8            | 709 623           | 0%             | N/A                               | Unlikely                   | Moderate                 |
| Physiological markers                                              |                             |              |                   |                |                                   |                            |                          |
| Early pregnancy <sup>f</sup> sBP 120–129<br>and dBP < 80 mmHg [35] | RR 2.38<br>(1.88, 3.02)     | 1            | 1929              | N/A            | Lower in PE group                 | Probable                   | High                     |

(Continues)

TABLE 2 | (Continued)

| Biomarker                                                                  | Effect estimate<br>(95% CI)                       | N<br>studies | N<br>participants | I <sup>2</sup> | Direction of effect                     | Strength of<br>association | Certainty of<br>evidence |
|----------------------------------------------------------------------------|---------------------------------------------------|--------------|-------------------|----------------|-----------------------------------------|----------------------------|--------------------------|
| Early pregnancy <sup>f</sup> sBP<br>130–139 mmHg or dBP<br>80–89 mmHg [35] | RR 2.94<br>(2.34, 3.71)                           | 1            | 1871              | N/A            | Higher in PE group                      | Probable                   | High                     |
| Arterial stiffness [14, 36]                                                | OR 18.6<br>(3.72, 93.0)                           | 9            | 845               | 93%            | Increased levels as<br>a risk factor    | Definite                   | Moderate                 |
| Serum concentration of NO<br>(μmol/mL) [14, 37]                            | OR 0.17<br>(0.04, 0.81)                           | 9            | 600               | 95%            | Higher levels as a<br>protective factor | Definite                   | Moderate                 |
| Uterine artery Doppler—FVW<br>(1st trimester) [13, 38]                     | LR+ 4.0<br>(2.7, 6.0)<br>LR– 0.79<br>(0.74, 0.84) | 8            | 37 971            | N/A            | Abnormal FVW<br>as a risk factor        | Possible                   | Moderate                 |
| Early onset PE <sup>a</sup> [38]                                           | LR+ 6.1<br>(4.1, 8.9)<br>LR– 0.57<br>(0.48, 0.67) | 7            | 38 611            | N/A            | Abnormal FVW<br>as a risk factor        | Probable                   | Moderate                 |
| Late-onset PE <sup>a</sup> [38]                                            | LR+ 2.2<br>(1.9, 2.6)<br>LR– 0.87<br>(0.83, 0.91) | 3            | 33 879            | N/A            | Abnormal FVW<br>as a risk factor        | Possible                   | Moderate                 |
| Ophthalmic artery Doppler—<br>peak ratio [39]                              | AUC 0.89                                          | 6            | 866               | N/A            | Higher peak ratio<br>as a risk factor   | Definite                   | Low                      |
| Ophthalmic artery Doppler—<br>second peak systolic velocity [39]           | AUC 0.93                                          | 3            | 425               | N/A            | Higher second peak<br>as a risk factor  | Definite                   | Low                      |
| Other                                                                      |                                                   |              |                   |                |                                         |                            |                          |
| Female fetal sex [13, 40]                                                  | OR 1.04<br>(0.97, 1.12)                           | 11           | 219 575           | 39%            | N/A                                     | Unlikely                   | Low                      |
| Early onset PE <sup>a</sup> [40]                                           | OR 1.36<br>(1.17, 1.5)                            | 11           | 219 575           | 21%            | Higher in PE group                      | Possible                   | Moderate                 |
| Preterm PE <sup>d</sup> [40]                                               | OR 1.17<br>(1.02, 1.35)                           | 11           | 219 575           | 33%            | Higher in PE group                      | Possible                   | Moderate                 |
| Term PE <sup>d</sup> [40]                                                  | OR 0.96 (0.90, 1.01)                              | 11           | 219 575           | 0%             | N/A                                     | Unlikely                   | Low                      |

(Continues)

TABLE 2 | (Continued)

| Biomarker                                                | Effect estimate<br>(95% CI)                          | N<br>studies | N<br>participants | I <sup>2</sup> | Direction of effect               | Strength of<br>association | Certainty of<br>evidence |
|----------------------------------------------------------|------------------------------------------------------|--------------|-------------------|----------------|-----------------------------------|----------------------------|--------------------------|
| Early pregnancy <sup>f</sup> HbA1c<br>> 39 nmol/mol [41] | RR 2.02<br>(1.53, 2.66)                              | 5            | 28 203            | 0%             | Higher levels as<br>a risk factor | Probable                   | High                     |
| Mean platelet volume [42]                                | LR+ 2.58<br>(2.01, 3.31)<br>LR− 0.38<br>(0.28, 0.52) | 22           | 20 137            | 97%            | Higher levels as<br>a risk factor | Possible                   | Low                      |

Abbreviations: CI, confidence interval; CRP, C-reactive protein; DOR, diagnostic odds ratio; fL, femtoliters; FVW, flow velocity waveform; HbA1c, glycated haemoglobin; HLA—human leukocyte antigen; I<sup>2</sup>, measure of heterogeneity (I<sup>2</sup> > 50% significant variability between studies); IFN-γ, interferon-gamma; IL, interleukin; MOM, multiple of the median; NO, nitric oxide; OR, odds ratio; PAPP-A, pregnancy-associated plasma protein A; PC, platelet count; PE, pre-eclampsia; PIGF, placental growth factor; PP13, placental protein 13; RR, relative risk; sENG, soluble endothelial growth factor; sFLT-1, soluble fms-like tyrosine kinase-1; sHCA-G, soluble human leukocyte antigen-G; SMD, standard mean difference; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor; WMD, weighted mean difference; β-hCG, beta human chorionic gonadotropin. Strength of association: increasing depth of green fill to cells reflects increasing strength of association. Certainty of evidence: increasing depth of tan reflects increasing certainty of evidence.

<sup>a</sup>Early onset pre-eclampsia < 34 weeks; late-onset pre-eclampsia ≥ 34 weeks.

<sup>b</sup>As reported in the source reference listed by biomarker; likely lower levels as a risk factor.

<sup>c</sup>As reported in the source reference listed by the biomarker; likely higher levels as a risk factor.

<sup>d</sup>Preterm pre-eclampsia < 37 weeks; term pre-eclampsia ≥ 37 weeks.

<sup>e</sup>Total sample of the review; numbers not reported for separate biomarkers.

<sup>f</sup>< 20 week.

both PIGF and anticardiolipin antibodies. Early pregnancy (<20 weeks) elevated blood pressure demonstrated evidence of a dose effect, with larger effect sizes found for higher blood pressure levels [35].

Four biomarkers had a possible association with pre-eclampsia. These included AB blood group [34] and first-trimester abnormal flow velocity waveform (FVW) on uterine artery Doppler [13, 38], based on moderate-quality evidence, and alpha-fetoprotein (AFP) [13, 23] and mean platelet volume (MPV) [42] based on low-quality evidence. Evidence was downgraded due to concerns about heterogeneity across the four possible biomarkers, a lack of reporting on publication bias for AFP, and risk of bias for MPV.

Six biomarkers were identified as unlikely to have an association with pre-eclampsia. These included O blood group [34] based on high-quality evidence, A blood group [34] and B blood group [34], based on moderate-quality evidence due to wide confidence intervals (imprecision). IL (interleukin)- 18 [14, 30], female fetal sex [13, 40], and human leukocyte antigen (HLA) antibodies [14, 31] were based on low- to very low-quality evidence due to concerns about the risk of bias, heterogeneity, and/or wide confidence intervals.

Ten biomarkers' strength of association could not be determined due to statistics not based on point estimates of summary measures (i.e., OR, RR, LR and AUROC point estimates), as described in our methodology. These included HDL-c [13, 27], LDL-c [13, 27], total cholesterol [13, 27], triglycerides [13, 27], C-reactive protein (CRP) [29], IL-4 [29], IL-6 [29], IL-8 [29], tumour necrosis factor (TNF-α) [29], and soluble human leukocyte antigen-G (sHCA-G) [33].

Comparisons between the timing of measurement and the onset of pre-eclampsia were reported for a limited number of biomarkers. PIGF [22], hCG > 2.0 multiples of the median (MoM) [24], PAPP-A [22], and female fetal sex [40] were significantly associated with early-onset or preterm pre-eclampsia, and unlikely to be associated with late-onset or term pre-eclampsia. First trimester uterine artery Doppler flow velocity waveforms had a probable association with early-onset pre-eclampsia, while only a possible association with late-onset pre-eclampsia [38]. Levels of sENG [22] and inhibin-A [22] were associated with both early- and late-onset pre-eclampsia. There were no biomarkers identified specifically for late-onset or term pre-eclampsia. β-hCG levels [26] may only be significantly associated with pre-eclampsia when measured in the 2nd trimester (not the 1st), and women with pre-eclampsia may have lower HDL-c levels [13, 27] specifically in the 3rd trimester.

#### 4 | Discussion

Based on the systematic literature, this conceptual framework finds that the strongest biomarkers predictive of pre-eclampsia are markers of angiogenic imbalance (PIGF, sENG, sFlt-1, VEGF) and fetal placental unit function (β-hCG, inhibin-A, PAPP-A, PP13), all with definite or probable associations based on moderate to high quality of evidence (Table 3). It is known that pre-eclampsia is partly mediated by dysfunctional

**TABLE 3** | Summary of biomarkers for overall pre-eclampsia by strength of association and quality of the evidence.

| Quality of the evidence     |                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                   |                                                                                                                                                                              |                                                                  |
|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| Strength of the association | High                                                                                                                                                                                                                                                                                                                                                              | Moderate                                                                                                                                                          | Low                                                                                                                                                                          | Very low                                                         |
| Definite                    | <ul style="list-style-type: none"><li>• Higher VEGF</li><li>• Higher <math>\beta</math>-hCG</li><li>• Abnormal Inhibin-A</li><li>• Abnormal PP13</li><li>• Higher IFN-<math>\gamma</math></li></ul>                                                                                                                                                               | <ul style="list-style-type: none"><li>• Arterial stiffness</li><li>• Higher serum concentration of NO</li></ul>                                                   | <ul style="list-style-type: none"><li>• Higher peak ratio on ophthalmic artery Doppler</li><li>• Higher second peak systolic velocity on ophthalmic artery Doppler</li></ul> |                                                                  |
|                             | <ul style="list-style-type: none"><li>• Higher sENG</li><li>• Higher sFlt-1</li><li>• Abnormal PAPP-A</li><li>• Early pregnancy sBP 120–129 and dBP &lt; 80 mmHg</li><li>• Early pregnancy sBP 130–139 mmHg or dBP 80–89 mmHg</li><li>• Higher early pregnancy HbA1c</li><li>• Ischaemia-modified albumin</li><li>• Uric acid</li><li>• Malondialdehyde</li></ul> | <ul style="list-style-type: none"><li>• Higher PlGF</li><li>• Higher antidiolipin antibodies</li></ul>                                                            |                                                                                                                                                                              |                                                                  |
| Possible                    |                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                   |                                                                                                                                                                              |                                                                  |
| Unlikely                    | <ul style="list-style-type: none"><li>• O blood group</li></ul>                                                                                                                                                                                                                                                                                                   | <ul style="list-style-type: none"><li>• AB blood group</li><li>• Abnormal FVW on uterine artery Doppler</li><li>• A blood group</li><li>• B blood group</li></ul> | <ul style="list-style-type: none"><li>• Higher AFP</li><li>• Higher MVP</li><li>• IL-18</li><li>• Female fetal sex</li></ul>                                                 | <ul style="list-style-type: none"><li>• HLA antibodies</li></ul> |

Note: Green text associated with decreased risk; red text associated with increased risk.

syncytiotrophoblast, placental dysfunction, and angiogenic imbalance [2, 43, 44].

Physiological markers, including elevated blood pressure in early pregnancy (SBP 120–129 and DBP <80 mmHg; 130–139 mmHg or DBP 80–89 mmHg), arterial stiffness and serum NO, were also identified by our model with definite or probable associations based on moderate-high quality of evidence. Several lipid metabolism and oxidative stress biomarkers and inflammatory and immune biomarkers demonstrated potential associations with the initiation of pre-eclampsia, but the point estimates of various summary measures could not be applied to determine the strength of association in our methodology.

A combination of biomarkers, maternal history and risk factors has contributed to reliable and cost-effective methods of prediction of pre-eclampsia [6–9]. For example, screening by maternal factors, uterine artery pulsatility index and serum PIGF predicted 90% of early-onset pre-eclampsia, 75% of preterm pre-eclampsia and 41% of term pre-eclampsia [6]. Responding to this risk with 150 mg aspirin nightly until 36 weeks' gestation cost-effectively reduces the odds of preterm disease by 62% [7, 9]. Our standardised method of prioritising umbrella reviews over even very large cohort studies with randomised controlled trial support has resulted in downgrading the bodies of evidence that support the validated 1st and 3rd trimester screening competing risk models [6, 8]. An updated umbrella review that reflects these data is required as excellent quality evidence has been downgraded.

There are other limitations to this study. For a few studies, the strength of association could not be evaluated based on point estimates of various summary measures (OR, RR, DOR, LR and AUC point estimates) that had been determined in the methods. Instead, some were reported in terms of mean differences and sensitivity and specificity of prediction models. Future work should involve using a tool which can determine the strength of association for these studies and prevent the exclusion of promising studies.

The conceptual framework for the predictive determinants of pre-eclampsia has several strengths. First, it allows the examination of the complex relationships that have not been undertaken previously for pre-eclampsia. Second, the evidence used in the conceptual model is derived from published peer-reviewed literature and can be updated with the latest evidence (e.g., competing risks models). Most of the evidence came from umbrella reviews or systematic reviews. Lastly, the conceptual framework highlights where evidence is lacking and requires further research.

## 5 | Conclusion

In brief, this hierarchical systematic literature review integrated 40 biomarkers into a conceptual framework for pre-eclampsia. These markers, with their known functions, provide additional potential for their use for stratifying pre-eclampsia risk, as well as further insights into disease pathophysiology. These data provide the best summary evidence for biomarker choice that might guide the constituent components and selection of

screening tests to guide ASA prescription, antenatal care pathways, or timing of birth. Our results highlight the biomarkers most strongly linked with pre-eclampsia diagnosis, offering valuable guidance for future evidence-based clinical investigations and interventions.

## Author Contributions

L.A.M., P.v.D., V.F., M.-L.V., T.E., and H.D.M. conceptualised and designed the study. L.A.M., P.v.D., T.E., and H.D.M. developed the methodology, and T.E. conducted the data collection. T.E. and M.-L.W.K. performed the data analysis and interpretation. T.E., M.-L.W.K., and H.D.M. drafted the original manuscript. T.E., M.-L.W.K., and H.D.M. reviewed and edited the manuscript for critical intellectual content. L.A.M. and P.v.D. supervised the research project. All authors read and approved the final version of the manuscript. The PRECISE Network contributed to study design and provided constructive challenges as part of the development of a suite of conceptual frameworks for placental disorders.

## Acknowledgements

This manuscript is part of the PRECISE (PREgnancy Care Integrating translational Science, Everywhere) Network. The authors would like to express their gratitude to the PRECISE Team and Pathways to Preeclampsia patient partners for their support.

## The PRECISE Network

Collaborators: Umberto D'Alessandro, Anna Roca, Hawanatu Jah, Andrew Prentice, Melisa Martinez-Alvarez, Brahim Diallo, Abdul Sesay, Sambou Suso, Baboucar Njie, Fatima Touray, Yahaya Idris, Fatoumata Kongira, Modou F. S. Ndure, Lawrence Gibba, Abdoulie Bah, Yorro Bah, Marleen Temmerman, Angela Koech, Patricia Okiro, Geoffrey Omuse, Grace Mwashigadi, Mary Goretti Amondi, Consolata Juma, Joseph Mutunga, Moses Mukhanya, Robin Okello, Onesmus Wanje, Isaac Mwaniki, Marvin Ochieng, Emily Mwandime, Esperanca Sevene, Corssino Tchavana, Salesio Macuacua, Anifa Vala, Helena Boone, Lazaro Quimice, Sonia Maculuvu, Inacio Mandomando, Peter von Dadelszen, Laura A. Magee, Rachel Craik, Marie-Laure Volvert, Hiten Mistry, Thomas Mendy, Donna Russell, Prestige Tatenda Makanga, Liberty Makacha, Reason Mlambo, Lucilla Poston, Rachel Tribe, Sophie Moore, Tatiana Salisbury, Aris Papageorgiou, Alison Noble, Rachel Craik, Hannah Blencowe, Veronique Filippi, Joy Lawn, Matt Silver, Joseph Akuze, Ursula Gazeley, Judith Cartwright, Guy Whitley, Sanjeev Krishna, Marianne Vidler, Jing Li, Jeff Bone, Mai-Lei Woo Kinshella, Domena Tu, Ash Sandhu, Kelly Pickerill, Carla Carillho, Benjamin Barratt.

## Ethics Statement

The review only utilised data from previously published studies.

## Conflicts of Interest

The authors declare no conflicts of interest.

## Data Availability Statement

The data that supports the findings of this study are available in the [Supporting Information](#) of this article.

## References

1. M. A. Brown, L. A. Magee, L. C. Kenny, et al., "Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice," *Hypertension* 72, no. 1 (2018): 24–43.

2. L. A. Magee, K. H. Nicolaides, and P. von Dadelszen, "Preeclampsia," *New England Journal of Medicine* 386, no. 19 (2022): 1817–1832.
3. L. Bellamy, J. P. Casas, A. D. Hingorani, and D. J. Williams, "Pre-Eclampsia and Risk of Cardiovascular Disease and Cancer in Later Life: Systematic Review and Meta-Analysis," *BMJ* 335, no. 7627 (2007): 974.
4. K. J. Chang, K. M. Seow, and K. H. Chen, "Preeclampsia: Recent Advances in Predicting, Preventing, and Managing the Maternal and Fetal Life-Threatening Condition," *International Journal of Environmental Research and Public Health* 20, no. 4 (2023): 2994.
5. M. Rybak-Krzyszowska, J. Staniczek, A. Kondracka, et al., "From Biomarkers to the Molecular Mechanism of Preeclampsia—A Comprehensive Literature Review," *International Journal of Molecular Sciences* 24, no. 17 (2023): 13252.
6. M. Y. Tan, A. Syngelaki, L. C. Poon, et al., "Screening for Preeclampsia by Maternal Factors and Biomarkers at 11–13 Weeks' Gestation," *Ultrasound in Obstetrics & Gynecology* 52, no. 2 (2018): 186–195.
7. D. L. Rolnik, D. Wright, L. C. Poon, et al., "Aspirin Versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia," *New England Journal of Medicine* 377, no. 7 (2017): 613–622, <https://doi.org/10.1056/NEJMoa1704559>.
8. A. Panaitescu, A. Ciobanu, A. Syngelaki, A. Wright, D. Wright, and K. H. Nicolaides, "Screening for Pre-eclampsia at 35–37 Weeks' Gestation," *Ultrasound in Obstetrics & Gynecology* 52, no. 4 (2018): 501–506.
9. D. Ortved, T. L. A. Hawkins, J. A. Johnson, J. Hyett, and A. Metcalfe, "Cost-Effectiveness of First-Trimester Screening With Early Preventative Use of Aspirin in Women at High Risk of Early-Onset Pre-eclampsia," *Ultrasound in Obstetrics & Gynecology* 53, no. 2 (2019): 239–244.
10. T. Elawad, G. Scott, J. N. Bone, et al., "Risk Factors for Pre-eclampsia in Clinical Practice Guidelines: Comparison With the Evidence," *British Journal of Obstetrics and Gynaecology* 131, no. 1 (2024): 46–62, <https://doi.org/10.1111/1471-0528.17320>.
11. R. A. Hiatt, T. C. Porco, F. Liu, et al., "A Multilevel Model of Postmenopausal Breast Cancer Incidence," *Cancer Epidemiology, Biomarkers & Prevention* 23, no. 10 (2014): 2078–2092.
12. P. von Dadelszen, M. Flint-O'Kane, L. Poston, et al., "The PRECISE (PREgnancy Care Integrating Translational Science, Everywhere) Network's First Protocol: Deep Phenotyping in Three Sub-Saharan African Countries," *Reproductive Health* 17, no. 1 (2020): 51.
13. R. Townsend, A. Khalil, Y. Premakumar, et al., "Prediction of Preeclampsia: Review of Reviews," *Ultrasound in Obstetrics & Gynecology* 54, no. 1 (2019): 16–27.
14. K. Giannakou, E. Evangelou, and S. I. Papatheodorou, "Genetic and Non-Genetic Risk Factors for Pre-eclampsia: Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies," *Ultrasound in Obstetrics & Gynecology* 51, no. 6 (2018): 720–730.
15. M. L. W. Kinshella, K. Pickerill, J. N. Bone, et al., "An Evidence Review and Nutritional Conceptual Framework for Pre-eclampsia Prevention," *British Journal of Nutrition* 130, no. 6 (2023): 1065–1076.
16. G. H. Guyatt, A. D. Oxman, H. J. Schünemann, P. Tugwell, and A. Knottnerus, "GRADE Guidelines: A New Series of Articles in the Journal of Clinical Epidemiology," *Journal of Clinical Epidemiology* 64, no. 4 (2011): 380–382.
17. G. H. Guyatt, A. D. Oxman, S. Sultan, et al., "GRADE Guidelines: 9. Rating Up the Quality of Evidence," *Journal of Clinical Epidemiology* 64, no. 12 (2011): 1311–1316.
18. A. J. Viera, "Odds Ratios and Risk Ratios: What's the Difference and Why Does It Matter?," *Southern Medical Journal* 101, no. 7 (2008): 730–734.
19. N. Mahutte and A. Duleba, "Evaluating Diagnostic Tests," [Internet] UpToDate (2024), <https://www.uptodate.com/contents/evaluating-diagnostic-tests#H15>.
20. J. N. Mandrekar, "Receiver Operating Characteristic Curve in Diagnostic Test Assessment," *Journal of Thoracic Oncology* 5, no. 9 (2010): 1315–1316.
21. C. E. Kleinrouweler, M. M. J. Wiegerinck, C. Ris-Stalpers, et al., "Accuracy of Circulating Placental Growth Factor, Vascular Endothelial Growth Factor, Soluble Fms-Like Tyrosine Kinase 1 and Soluble Endoglin in the Prediction of Pre-eclampsia: A Systematic Review and Meta-Analysis," *British Journal of Obstetrics and Gynaecology* 119, no. 7 (2012): 778–787.
22. R. E. Allen, E. Rogozinska, K. Cleverly, J. Aquilina, and S. Thangaratinam, "Abnormal Blood Biomarkers in Early Pregnancy Are Associated With Preeclampsia: A Meta-Analysis," *European Journal of Obstetrics, Gynecology, and Reproductive Biology* 182 (2014): 194–201.
23. R. K. Morris, J. S. Cnossen, M. Langejans, et al., "Serum Screening With Down's Syndrome Markers to Predict Pre-eclampsia and Small for Gestational Age: Systematic Review and Meta-Analysis," *BMC Pregnancy and Childbirth* 8 (2008): 33.
24. S. Tancrede, E. Bujold, Y. Giguère, M. H. Renald, J. Girouard, and J. C. Forest, "Mid-Trimester Maternal Serum AFP and hCG as Markers of Preterm and Term Adverse Pregnancy Outcomes," *Journal of Obstetrics and Gynaecology Canada* 37, no. 2 (2015): 111–116.
25. H. Q. Liu, Y. H. Wang, L. L. Wang, and M. Hao, "Predictive Value of Free  $\beta$ -hCG Multiple of the Median for Women With Preeclampsia," *Gynecologic and Obstetric Investigation* 81, no. 2 (2016): 137–147.
26. X. Zhang, Z. Huangfu, F. Shi, and Z. Xiao, "Predictive Performance of Serum  $\beta$ -hCG MoM Levels for Preeclampsia Screening: A Meta-Analysis," *Frontiers in Endocrinology* 12 (2021): 619530.
27. C. N. Spracklen, C. J. Smith, A. F. Saftlas, J. G. Robinson, and K. K. Ryckman, "Maternal Hyperlipidemia and the Risk of Preeclampsia: A Meta-Analysis," *American Journal of Epidemiology* 180, no. 4 (2014): 346–358.
28. D. Afrose, H. Chen, A. Ranasinghe, et al., "The Diagnostic Potential of Oxidative Stress Biomarkers for Preeclampsia: Systematic Review and Meta-Analysis," *Biology of Sex Differences* 13, no. 1 (2022): 26.
29. X. Guan, Y. Fu, Y. Liu, et al., "The Role of Inflammatory Biomarkers in the Development and Progression of Pre-eclampsia: A Systematic Review and Meta-Analysis," *Frontiers in Immunology* 14 (2023): 1156039, <https://doi.org/10.3389/fimmu.2023.1156039/full>.
30. Y. Yang, X. Su, W. Xu, and R. Zhou, "Interleukin-18 and Interferon Gamma Levels in Preeclampsia: A Systematic Review and Meta-Analysis," *American Journal of Reproductive Immunology* 72, no. 5 (2014): 504–514.
31. E. E. L. O. Lashley, T. Meuleman, and F. H. J. Claas, "Beneficial or Harmful Effect of Antipaternal Human Leukocyte Antibodies on Pregnancy Outcome? A Systematic Review and Meta-Analysis," *American Journal of Reproductive Immunology* 70, no. 2 (2013): 87–103.
32. A. do P, P. Dm, S. Hl, and H. Bl, "Association of Anticardiolipin Antibodies With Preeclampsia: A Systematic Review and Meta-Analysis," *Obstetrics and Gynecology* 116, no. 6 (2010): 1433–1443.
33. A. Bhattarai, S. Shah, K. Dahal, et al., "Biomarker Role of Maternal Soluble Human Leukocyte Antigen G in Pre-eclampsia: A Meta-Analysis," *Immunity, Inflammation and Disease* 12, no. 4 (2024): e1254.
34. T. Li, Y. Wang, L. Wu, et al., "The Association Between ABO Blood Group and Preeclampsia: A Systematic Review and Meta-Analysis," *Frontiers in Cardiovascular Medicine* 8 (2021): 665069.
35. M. Reddy, D. L. Rolnik, K. Harris, et al., "Challenging the Definition of Hypertension in Pregnancy: A Retrospective Cohort Study," *American Journal of Obstetrics and Gynecology* 222, no. 6 (2020): 606.e1–606.e21.
36. A. Hausvater, T. Giannone, Y. H. G. Sandoval, et al., "The Association Between Preeclampsia and Arterial Stiffness," *Journal of Hypertension* 30, no. 1 (2012): 17–33.

37. B. Dai, T. Liu, B. Zhang, X. Zhang, and Z. Wang, "The Polymorphism for Endothelial Nitric Oxide Synthase Gene, the Level of Nitric Oxide and the Risk for Pre-eclampsia: A Meta-Analysis," *Gene* 519, no. 1 (2013): 187–193.
38. L. Velauthar, M. N. Plana, M. Kalidindi, et al., "First-Trimester Uterine Artery Doppler and Adverse Pregnancy Outcome: A Meta-Analysis Involving 55 974 Women," *Ultrasound in Obstetrics & Gynecology* 43, no. 5 (2014): 500–507.
39. P. F. M. V. de Melo, L. Roever, T. M. S. Mendonça, F. da Silva Costa, D. L. Rolnik, and A. L. D. Diniz, "Ophthalmic Artery Doppler in the Complementary Diagnosis of Preeclampsia: A Systematic Review and Meta-Analysis," *BMC Pregnancy and Childbirth* 23, no. 1 (2023): 343.
40. S. Schalekamp-Timmermans, L. R. Arends, E. Alsaker, et al., "Fetal Sex-Specific Differences in Gestational Age at Delivery in Pre-eclampsia: A Meta-Analysis," *International Journal of Epidemiology* 46, no. 2 (2017): 632–642.
41. L. Mañé, H. Navarro, J. Pedro-Botet, et al., "Early HbA1c Levels as a Predictor of Adverse Obstetric Outcomes: A Systematic Review and Meta-Analysis," *Journal of Clinical Medicine* 13, no. 6 (2024): 1732.
42. D. Ye, S. Li, Y. Ding, Z. Ma, and R. He, "Clinical Value of Mean Platelet Volume in Predicting and Diagnosing Pre-eclampsia: A Systematic Review and Meta-Analysis," *Frontiers in Cardiovascular Medicine* 10 (2023): 1251304, <https://doi.org/10.3389/fcvm.2023.1251304>.
43. R. J. Levine, S. E. Maynard, C. Qian, et al., "Circulating Angiogenic Factors and the Risk of Preeclampsia," *New England Journal of Medicine* 350, no. 7 (2004): 672–683.
44. J. Tomkiewicz and D. A. Darmochwał-Kolarz, "Biomarkers for Early Prediction and Management of Preeclampsia: A Comprehensive Review," *Medical Science Monitor* 30 (2024): e944104.

### Supporting Information

Additional supporting information can be found online in the Supporting Information section.